Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
 
May 10 Life Science Leader's May issue includes results from Nice Insight annual research April 10 Learn about Trends in Outsourcing the Oral Solid Dose in April's Outsourcing Insights 
"Nice Insight offers a unique perspective by tracking critical data relating
to the pharmaceutical CRO/CMO marketplace. The data they garner, as well as
their overall approach, puts them in a leading position for market
research."
Jeff Reinke editorial director, Pharmaceutical Processing & Manufacturing.net  
BioProcess International Conference
September 16-20 Boston, MA |
American Peptide Company, Inc. Chesapeake PERL Cook Pharmica Maine Biotechnology Services, Inc. Novolyte Technologies Paragon Bioservices, Inc. Phoenix Pharmaceuticals, Inc. QED Bioscience, Inc.
QED Bioscience, Inc. develops and manufactures novel monoclonal and polyclonal antibody products for academic, biotechnology, diagnostic and pharmaceutical research clients. Antibodies are developed using a client's small molecule, protein, or peptide targets, or by utilizing the target cDNA. Additional immunochemistry services include purification and conjugation. The company also develops monoclonal antibodies with pharmacological activity for enzyme neutralization and inhibition of receptor-ligand interactions and anti-idiotypic antibodies. The company offers over 1,500 monoclonal and polyclonal antibodies for various applications in cancer research, neuroscience, signal transduction, infectious disease, and other research areas. http://www.qedbio.com
Regions
Americas Stock Symbol Private Filter of QED Bioscience, Inc.'s services per Nice Insight Categories
Contact QED Bioscience, Inc. 
|
|
|
